Advertisement

Annals of Behavioral Medicine

, Volume 40, Issue 3, pp 235–247 | Cite as

Dynamics of Changes in Self-Efficacy and Locus of Control Expectancies in the Behavioral and Drug Treatment of Severe Migraine

  • Elizabeth K. SengEmail author
  • Kenneth A. Holroyd
Original Article

Abstract

Background

Modification of expectancies (headache self-efficacy and headache locus of control) is thought to be central to the success of psychological treatments for migraine.

Purpose

The purpose of this study is to examine expectancy changes with various combinations of Behavioral Migraine Management and migraine drug therapies.

Methods

Frequent migraine sufferers who failed to respond to 5 weeks of optimized acute migraine drug therapy were randomized to a 2 (Behavioral Migraine Management+, Behavioral Migraine Management−) × 2 (β-blocker, placebo) treatment design.

Results

Mixed models for repeated measures analyses (N = 176) revealed large increases in headache self-efficacy and internal headache locus of control and large decreases in chance headache locus of control with Behavioral Migraine Management+ that were maintained over a 12-month evaluation period. Chance headache locus of control and socioeconomic status moderated changes in headache self-efficacy with Behavioral Migraine Management+.

Conclusions

The “deficiency” hypothesis best explained how patient characteristics influenced changes in of headache self-efficacy with Behavioral Migraine Management.

Keywords

Migraine Behavioral treatment Drug treatment Self-efficacy Locus of control Socioeconomic status 

Notes

Acknowledgments

We would like to thank the following people for their assistance in carrying out the TSM trial: Constance Cottrell, Francis O’Donnell, Gary Cordingley, Carol Nogrady, Kimberly Hill, Victor Heh, Suzanne Smith, Bernadette Devantes Heckman, Brenda Pinkerman, Gregg Tkachuk, Sharon Waller, Donna Shiels, Kathleen Darchuk, Yi Chen, Timur Skeini, Manish Singla, Swati Dalmai, Lori Arnott, and Lina Himawan. Support for this trial was provided by grant NS-32374 (awarded to Dr. Holroyd) from the National Institutes of Health. Merck Pharmaceuticals, Inc and GlaxoSmithKline Pharmaceuticals donated triptans (5-HT1B/D-agonists) for acute migraine therapy, which was their only involvement.

Conflict of Interest Statement

Ms. Seng reports no conflicts of interest. Dr. Holroyd has received support from the National Institutes of Health (NINDS; NS32375), has consulted for ENDO Pharmaceuticals and Takeda Pharmaceuticals North America, and received an investigator initiated grant from ENDO Pharmaceuticals.

References

  1. 1.
    Nestoriuc Y, Martin A: Efficacy of biofeedback for migraine: A meta-analysis. Pain. 2007, 128:111–127.CrossRefPubMedGoogle Scholar
  2. 2.
    Penzien D, Rains J, Andrasik F: Behavioral management of recurrent headache: Three decades of experience and empiricism. Appl Psychophysiol Biofeedback. 2002, 27:163–181.CrossRefPubMedGoogle Scholar
  3. 3.
    Campbell J, Penzien D, Wall E: Evidence-based guidelines for migraine headache: Behavioral and physical treatments. American Academy of Neurology Guidelines 2000. Retrieved May 03, 2010, from www.aan.com/professionals/practice/pdfs/gl0089.pdf
  4. 4.
    Holroyd K, Penzien D: Pharmacological vs. nonpharmacological prophylaxis of recurrent migraine headache: A meta-analytic review of clinical trials. Pain. 1990, 42:1–13.CrossRefPubMedGoogle Scholar
  5. 5.
    Silberstein S: Practice Parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Neurology. 2000, 55:754–762.PubMedGoogle Scholar
  6. 6.
    Bandura A: Self-efficacy: Toward a unifying theory of behavioral change. Psychol Rev. 1977, 84:191–215.CrossRefPubMedGoogle Scholar
  7. 7.
    Bandura A: Self-efficacy: The exercise of control. New York: W.H. Freeman, 1997.Google Scholar
  8. 8.
    Rotter JB: Generalized expectancies for internal versus external control of reinforcement. Psychol Monogr. 1966, 80:1–28.PubMedGoogle Scholar
  9. 9.
    Bodenheimer T, Lorig K, Holman H, Grumbach K: Patient self management of chronic disease in primary care. JAMA. 2002, 288:2469–2475.CrossRefPubMedGoogle Scholar
  10. 10.
    Marks R, Allegrante J, Lorig K: A review and synthesis of research evidence for self-efficacy-enhancing interventions for reducing chronic disability: Implications for health education practice. Health Promote Pract. 2005, 6:37–43.CrossRefGoogle Scholar
  11. 11.
    Tobin D, Reynolds R, Holroyd K, Creer T: Self-management and social learning theory. In K. Holroyd and T. Creer (eds), Self-management of chronic disease: Handbook of clinical interventions and research. New York: Academic Press, 1986.Google Scholar
  12. 12.
    Rains J, Penzien D, Lipchik G: Behavioral facilitation of medical treatment for headache part II: Theoretical models and behavioral strategies for improving adherence. Headache. 2006, 46:1395–1403.CrossRefPubMedGoogle Scholar
  13. 13.
    Nicholson RA, Hursey RG, Nash JM: Moderators and mediators of behavioral treatment for headache. Headache. 2005, 45:513–519.CrossRefPubMedGoogle Scholar
  14. 14.
    Holroyd K, Penzien D, Rains J, Lipchik G, Buse D: Behavioral management of headaches. In S. Silberstein, R. Lipton and D. Dodick (eds), Wolff's Headache and Other Head Pain. New York, NY: Oxford University Press, 2008, 721–746.Google Scholar
  15. 15.
    Holroyd K, Martin P: Psychological treatments for tension-type headache. In J. Olesen, P. Tfelt-Hansen and K. Welch (eds), The headaches. Philadelphia: Lippincott Williams & Wilkins, 2000, 643–649.Google Scholar
  16. 16.
    French DJ, Holroyd KA, Pinnell C, et al.: Perceived self-efficacy and headache-related disability. Headache. 2000, 40:647–656.CrossRefPubMedGoogle Scholar
  17. 17.
    Holroyd KA, Labus J, Carlson BW: Moderation and mediation in the psychological and drug treatment of chronic tension-type headache: The role of disorder severity and psychiatric comorbidity. Pain. 2009, 143:213–222.CrossRefPubMedGoogle Scholar
  18. 18.
    Rokicki LA, Holroyd KA, France CR, et al.: Change mechanisms associated with combined relaxation/EMG biofeedback training for chronic tension headache. Appl Psychophysiol Biofeedback. 1997, 22:21–41.CrossRefPubMedGoogle Scholar
  19. 19.
    Nestoriuc Y, Rief W, Martin A: Meta-analysis of biofeedback for tension-type headache: Efficacy, specificity, and treatment moderators. J Consult Clin Psychol. 2008, 76:379–396.CrossRefPubMedGoogle Scholar
  20. 20.
    Holroyd KA, Malinoski PT, Carlson BW: Patient characteristics and treatment adherence predict response to antidepressant medication and to cognitive-behavior therapy for chronic tension-type headache. Ann. Behav. Med. 2002, 24:S050.Google Scholar
  21. 21.
    Nicholson R, Nash J, Andrasik: A self-administered behavioral intervention using tailored messages for migraine. Headache. 2005, 45:1124–1139.CrossRefPubMedGoogle Scholar
  22. 22.
    Thorn BE, Pence LB, Ward LC, et al.: A randomized clinical trial of targeted cognitive behavioral treatment to reduce catastrophizing in chronic headache sufferers. J Pain. 2007, 8:938–949.CrossRefPubMedGoogle Scholar
  23. 23.
    Mizener D, Thomas M, Billings R: Cognitive changes of migraineurs receiving biofeedback training. Headache. 1988, 28:339–343.CrossRefPubMedGoogle Scholar
  24. 24.
    Lee S, Park J, Kim M: Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: A randomized, prospective, parallel group, double-blind, placebo-controlled study. Headache. 2005, 45:7.CrossRefGoogle Scholar
  25. 25.
    Martin NJ, Holroyd KA, Penzien DB: The headache-specific locus of control scale: Adaptation to recurrent headaches. Headache. 1990, 30:729–734.CrossRefPubMedGoogle Scholar
  26. 26.
    Wallston KA: The Validity of the Multidimensional Health Locus of Control Scales. J Health Psychol. 2005, 10:623–631.CrossRefPubMedGoogle Scholar
  27. 27.
    Nicholson RA, Houle TT, Rhudy JL, Norton PJ: Psychological Risk Factors in Headache. Headache. 2007, 47:413–426.PubMedGoogle Scholar
  28. 28.
    Hollon SD, DeRubeis J: Placebo-psychotherapy combinations: Inappropriate representations of psychotherapy in drug-psychotherapy comparative trials. Psychol Bull. 1981, 90:467–477.CrossRefPubMedGoogle Scholar
  29. 29.
    Cox DJ, Freundlich, A., Meyer, R.G.: Differential effectiveness of electromyograph feedback, verbal relaxation instructions, and medication placebo with tension headaches. J Consult Clin Psychol. 1975, 43:892–898.CrossRefPubMedGoogle Scholar
  30. 30.
    Sotsky SM, Glass DR, Shea MT, Pilkonis PA, et al.: Patient predictors of response to psychotherapy and pharmacotherapy: Findings in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry. 1991, 148:997–1008.PubMedGoogle Scholar
  31. 31.
    Holroyd K, Cottrell C, O'Donnell F, et al.: Does Preventive (Beta Blocker) Medication, Behavioral Migraine Management or Their Combination Improve Outcomes of Optimal Acute Therapy in Frequent Migraine: A Randomized Trial. Submitted.Google Scholar
  32. 32.
    Holroyd K, Cottrell C, O'Donnell F, et al.: Does preventive medication, behavioral migraine management or their combination add to optimal acute therapy in the management of frequent migraines: The TSM trial. Headache. 2006, 46:835.Google Scholar
  33. 33.
    Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988, 8:1–96.CrossRefGoogle Scholar
  34. 34.
    Holroyd K, Cottrell C, Echelberger-McCune R: Behavioral management for migraine headaches: A treatment program. Athens, OH: Ohio University Headache Treatment and Research Project, 2000.Google Scholar
  35. 35.
    Jhingran P, Osterhouse JT, Miller DW, Lee JT, Kirchdoerfer L: Development and validation of the migraine-specific quality of life questionnaire. Headache. 1998, 38:295–302.CrossRefPubMedGoogle Scholar
  36. 36.
    Heckman BD, Holroyd KA, Tietjen G, et al.: Whites and African-Americans in headache specialty clinics respond equally well to treatment. Headache. 2009, 29:650–661.Google Scholar
  37. 37.
    Williams DR, Collins C: US socioeconomic and racial differences in health: Patterns and explanations Annu Rev Sociol. 1995, 21:349.CrossRefGoogle Scholar
  38. 38.
    Leon AM, CH, Chuang-Stein C, Archibald D, Archer G, Chartier K: Attrition in randomized controlled clinical trials: Methodological issues in pyschopharmacology. Biol Psychiatry. 2006, 59:1001–1005.CrossRefPubMedGoogle Scholar
  39. 39.
    Mallinckrodt C, Clark W, David S: Accounting for dropout bias using mixed-effects models. J Biopharm Stat. 2001, 11:9–21.CrossRefPubMedGoogle Scholar
  40. 40.
    Mallinckrodt C, Clark W, David S: Type I error rates from mixed-effects model repeated measures versus fixed effects ANOVA with missing values imputed via last observation carried forward. Drug Inf J. 2001, 35:1215–1225.Google Scholar
  41. 41.
    Mallinckrodt C, Sanger T, Dube S, et al.: Assessing treatment effects in longitudinal data. Biol Psychiatry. 2003, 53:754–760.CrossRefPubMedGoogle Scholar
  42. 42.
    Molenberghs G, Thijs H, Jansen I, Beunckens C: Analyzing incomplete longitudinal clinical trial data. Biostatistics. 2004, 5:445–464.CrossRefPubMedGoogle Scholar
  43. 43.
    Barnes S, Mallinckrodt C, Lindborg S, Carter M: The impact of missing data and how it is handled on the rate of false-positive results in drug development. Pharm Statist. 2008, 7:215–225.CrossRefGoogle Scholar
  44. 44.
    Gadbury G, Coffey C, Allison D: Modern statistical methods for handling missing data. Obes Rev. 2003, 4:175–184.CrossRefPubMedGoogle Scholar
  45. 45.
    Lipchik G, Holroyd K, Nash J: Cognitive-behavioral management of recurrent headache disorders: A minimal-therapist contact approach. In D. Turk and R. Gatchel (eds), Psychological Approaches to Pain Management. New York, NY: Guilford Press, 2002, 356–389.Google Scholar
  46. 46.
    Lipton R, Bigal M, Diamond M, et al.: Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007, 68:343–349.CrossRefPubMedGoogle Scholar
  47. 47.
    Link BG, Phelan J: Social conditions as fundamental causes of disease. J Health Soc Behav. 1995, Spec No:80–94.Google Scholar
  48. 48.
    Brandes J: The migraine cycle: Patient burden of migraine during and between migraine attacks. Headache. 2008, 48:430–441.CrossRefPubMedGoogle Scholar
  49. 49.
    Silberstein S, Freitag F, Bigal M: Migraine treatment. In S. Silberstein, R. Lipton and D. Dodick (eds), Wolff's Headache and Other Head Pain. London: Oxford University Press, 2008, 177–292.Google Scholar
  50. 50.
    Ramadan N, Silberstein S, Freitag F, Gilbert T, Frishberg B: Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management for the prevention of migraine. American Academy of Neurology Guidelines 2002. Retrieved Accessed May 03 2010, from http://www.aan.com/professionals/practice/pdfs/gl0090.pdf
  51. 51.
    Steiner T, Paemeiere K, Jensen RV, D, et al.: European principles of management of common headache disorders in primary care. J Headache Pain. 2007, 8 S3–47.CrossRefPubMedGoogle Scholar
  52. 52.
    pt?>Kaniecki RL, S: Treatment of primary headache: Preventive treatment of migraine. Standards of care for headache diagnosis and treatment. Chicago: National Headache Foundation, 2004, 40–52.Google Scholar
  53. 53.
    Brandes J, Saper J, Diamond M, et al.: Topiramate for migraine prevention. JAMA. 2004, 291:965–973.CrossRefPubMedGoogle Scholar
  54. 54.
    Silberstein S, Neto W, Schmitt J, Jacobs D: Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol. 2004, 61:490–495.CrossRefPubMedGoogle Scholar
  55. 55.
    Diener H-C, Tfelt-Hansen P, Dahlof C, et al.: Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004, 251:943–950.CrossRefPubMedGoogle Scholar
  56. 56.
    French DJ, Gauthier JG, Roberge C, Nouwen A: Self-efficacy in the thermal biofeedback treatment of migraine sufferers. Beh Ther. 1997, 28:109–125.CrossRefGoogle Scholar
  57. 57.
    Holroyd KA, Penzien DB, Hursey K, et al.: Change mechanisms in EMG biofeedback training: Cognitive changes underlying improvements in tension headache. J Consult Clin Psychol. 1984, 52:1039–1053.CrossRefPubMedGoogle Scholar
  58. 58.
    Blanchard EB, Kim M, Hermann C, et al.: The role of perception of success in the thermal biofeedback treatment of vascular headache. Headache Q. 1994, 5:231–236.Google Scholar

Copyright information

© The Society of Behavioral Medicine 2010

Authors and Affiliations

  1. 1.Department of PsychologyOhio UniversityAthensUSA

Personalised recommendations